UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.061

Sortiert nach

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

Journal for immunotherapy of cancer, 2019-12, Vol.7 (1), p.354-20, Article 354

2019

Link zum Volltext

Verfügbarkeit prüfen

Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Therapy

Journal of clinical oncology, 2009-01, Vol.27 (2), p.235-241

2009

Link zum Volltext

Verfügbarkeit prüfen

Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab

Journal for immunotherapy of cancer, 2018-10, Vol.6 (1), p.107-107, Article 107

2018

Link zum Volltext

Verfügbarkeit prüfen

Overcoming Obstacles to Clinical Trial Recruitment and Retention

Oncology (Williston Park, N.Y.), 2023-11, Vol.37 (11), p.458

Wood, Laura S

2023

Link zum Volltext

Verfügbarkeit prüfen

Search for Evidence‐Based Approaches for the Prevention and Palliation of Hand–Foot Skin Reaction (HFSR) Caused by the Multikinase Inhibitors (MKIs)

The oncologist (Dayton, Ohio), 2009-03, Vol.14 (3), p.291-302

2009

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy

Journal for immunotherapy of cancer, 2019-05, Vol.7 (1), p.127-5, Article 127

2019

Link zum Volltext

Verfügbarkeit prüfen

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

Journal for immunotherapy of cancer, 2016-11, Vol.4 (1), p.81-81, Article 81

2016

Link zum Volltext

Verfügbarkeit prüfen

Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor

Advances in therapy, 2023-09, Vol.40 (9), p.3599-3609

2023

Link zum Volltext

Verfügbarkeit prüfen

Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016

Journal for Immunotherapy of Cancer, 2017-07, Vol.5 (1), p.55-55, Article 55

2017

Link zum Volltext

Verfügbarkeit prüfen

Correction to: Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor

Advances in therapy, 2023-09, Vol.40 (9), p.4116-4116

2023

Link zum Volltext

Verfügbarkeit prüfen

Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study

The lancet oncology, 2019-10, Vol.20 (10), p.1386-1394

2019

Link zum Volltext

Verfügbarkeit prüfen

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group

Clinical cancer research, 2021-05, Vol.27 (9), p.2416-2423

2021

Link zum Volltext

Verfügbarkeit prüfen

The Role of Nurses in the Management of Adverse Events in Patients Receiving First-Line Axitinib Plus Immuno-Oncology Agents for Advanced Renal Cell Carcinoma

Seminars in oncology nursing, 2024-02, Vol.40 (1), p.151545-151545, Article 151545

2024

Link zum Volltext

Verfügbarkeit prüfen

A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma

The Journal of urology, 2015-08, Vol.194 (2), p.297-303

2015

Link zum Volltext

Verfügbarkeit prüfen

Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non–Clear Cell Renal Cell Carcinoma

Clinical genitourinary cancer, 2020-12, Vol.18 (6), p.429-435

2020

Link zum Volltext

Verfügbarkeit prüfen

A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2017-06, Vol.35 (16), p.1764-1769

2017

Link zum Volltext

Verfügbarkeit prüfen

Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?

Case reports in oncological medicine, 2015-01, Vol.2015, p.817578-4

2015

Link zum Volltext

Verfügbarkeit prüfen

Immune-Related Adverse Events From Immunotherapy: Incorporating Care Step Pathways to Improve Management Across Tumor Types

Journal of the advanced practitioner in oncology, 2019-03, Vol.10 (Suppl 1), p.47-62

Wood, Laura S

2019

Link zum Volltext

Verfügbarkeit prüfen

Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses

Journal of infusion nursing, 2022-05, Vol.45 (3), p.142

2022

Link zum Volltext

Verfügbarkeit prüfen

Association of percentage of tumour burden removed with debulking nephrectomy and progression‐free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapy

BJU international, 2010-11, Vol.106 (9), p.1266-1269

2010

Link zum Volltext

Verfügbarkeit prüfen

Toxicity Management of Front-Line Pembrolizumab Combined With Axitinib in Clear Cell Metastatic Renal Cell Carcinoma: A Case Study Approach

JCO oncology practice, 2020-02, Vol.16 (2_suppl), p.15s-19s

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

Cancer, 2014-06, Vol.120 (11), p.1647-1655

2014

Link zum Volltext

Verfügbarkeit prüfen

Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma

Clinical genitourinary cancer, 2018-10, Vol.16 (5), p.413-419.e1

2018

Link zum Volltext

Verfügbarkeit prüfen

Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors

Clinical genitourinary cancer, 2019-06, Vol.17 (3), p.177-182

2019

Link zum Volltext

Verfügbarkeit prüfen

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial

Targeted oncology, 2015-03, Vol.10 (1), p.45-53

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 2.061

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.810)
Mit Volltextzugriff
(1.792)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.263)
Life Sciences & Biomedicine
(1.092)
Humans
(862)
Female
(464)
Male
(443)
Middle Aged
(277)
Adult
(273)
Aged
(210)
Oncology
(178)
Social Sciences
(162)
Biological And Medical Sciences
(160)
Animals
(155)
Medical Sciences
(124)
Mutation
(116)
Science & Technology - Other Topics
(107)
Adolescent
(105)
Patients
(102)
Child
(94)
Physical Sciences
(94)
Tumors
(94)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Therapy

Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab

Overcoming Obstacles to Clinical Trial Recruitment and Retention

Search for Evidence‐Based Approaches for the Prevention and Palliation of Hand–Foot Skin Reaction (HFSR) Caused by the Multikinase Inhibitors (MKIs)

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor

Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016

Correction to: Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor

Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group

The Role of Nurses in the Management of Adverse Events in Patients Receiving First-Line Axitinib Plus Immuno-Oncology Agents for Advanced Renal Cell Carcinoma

A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma

Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non–Clear Cell Renal Cell Carcinoma

A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma

Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?

Immune-Related Adverse Events From Immunotherapy: Incorporating Care Step Pathways to Improve Management Across Tumor Types

Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses

Association of percentage of tumour burden removed with debulking nephrectomy and progression‐free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapy

Toxicity Management of Front-Line Pembrolizumab Combined With Axitinib in Clear Cell Metastatic Renal Cell Carcinoma: A Case Study Approach

A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma

Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial

Suchergebnisse filtern